Docoh
Loading...

ADMP Adamis Pharmaceuticals

Filed: 27 May 21, 5:10pm
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K


CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 23, 2021


ADAMIS PHARMACEUTICALS CORPORATION

(Exact Name of Registrant as Specified in Charter)

 

Delaware 0-26372 82-0429727

(State or other jurisdiction

of incorporation)

 (Commission File Number) 

(IRS Employer

Identification No.)

 

11682 El Camino Real, Suite 300

San Diego, CA

 92130
(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: (858) 997-2400

(Former name or Former Address, if Changed Since Last Report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ADMP NASDAQ Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 

 

 

Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On May 23, 2021, the board of directors of Adamis Pharmaceuticals Corporation (the Company”) designated and appointed David C. Benedicto, the Company’s senior director of accounting and controller, as the Company’s principal accounting officer; previously, Robert O. Hopkins, the Company’s chief financial officer, served as the Company’s principal accounting officer. Mr. Benedicto, 60, joined the Company in December 2014, as accounting manager. Mr. Benedicto, a CPA and CMA (Certified Management Accountant), earned a Bachelor’s degree in Commerce from the University of Saint La Salle, and an M.B.A. from the University of the Redlands. The selection of Mr. Benedicto to serve as principal accounting officer was not made pursuant to any arrangement or understanding with any other person. The Company will enter into the Company’s form of indemnity agreement with Mr. Benedicto. There are no family relationships between Mr. Benedicto and any director or executive officer of the Company, and, except as set forth above, Mr. Benedicto does not have any other direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K.

 

Item 9.01Financial Statements and Exhibits

 

 

Exhibit No. Description 
   
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 ADAMIS PHARMACEUTICALS CORPORATION
   
   
   
Dated:  May 27, 2021By:/s/ Dennis J. Carlo 
 Name:Dennis J. Carlo
 Title:Chief Executive Officer